Treatment of extrahepatic cholangiocarcinoma
| Authors |
|
|---|---|
| Supervisors |
|
| Cosupervisors |
|
| Award date | 20-03-2026 |
| ISBN |
|
| Number of pages | 293 |
| Organisations |
|
| Abstract |
This thesis examines several key aspects of the treatment of extrahepatic cholangiocarcinoma (eCCA). The first part addresses novel developments, including regional collaborations and digitalization in hepatobiliary oncology care (Chapters 1–3). The second part concentrates on optimizing patient selection for surgical treatment in eCCA, investigating predictors of radical resection and the development of a novel clinical ABC staging system incorporating anatomical, biological, and conditional factors (Chapters 4–7). The third part discusses the effect and feasibility of induction treatment and describes the study protocol of the NEODISCO trial, which aims to investigate the effect of neoadjuvant gemcitabine and cisplatin combined with perioperative pembrolizumab on event-free survival in patients with resectable eCCA (Chapters 8–9).
|
| Document type | PhD thesis |
| Language | English |
| Downloads |
Thesis (complete)
(Embargo up to 2026-09-20)
Chapter 4: Predicting R1 resection in patients prior to pancreatoduodenectomy for distal cholangiocarcinoma: A nationwide cohort study
(Embargo up to 2026-09-20)
Chapter 7: An ABC approach for preoperative staging in perihilar cholangiocarcinoma: an international multicenter cohort study by the perihilar cholangiocarcinoma collaboration group
(Embargo up to 2026-09-20)
Chapter 9: Neoadjuvant gemcitabine and cisplatin in combination with perioperative pembrolizumab versus upfront surgery for patients with primary resectable and borderline resectable perihilar and distal cholangiocarcinoma (NEODISCO trial): Study protocol for a multicenter randomized controlled phase 2/3 trial
(Embargo up to 2026-09-20)
|
| Permalink to this page | |